Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.32 (market cap $2.81B), while Vanguard High Dividend Yield ETF trades at $159.85 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 35.9× Dyne Therapeutics Inc. Common Stock's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| DYN | VYM | |
|---|---|---|
Market Cap | $2.81B | $100.80B |
Volume | 2,195,902 | 1,062,392 |
Sector | Health | — |
52-Week High | $26.78 | $167.03 |
52-Week Low | $14.60 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $2.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VYM trades at $159.48, up 0.23% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 57.78 suggesting balanced momentum. Recent news highlights VYM's consistent dividend yield of 2.42% but notes competitive pressure from alternatives like SCHD and FDVV that offer higher returns and dividend growth.
Outlook remains cautious as VYM faces competition from higher-yielding ETFs and potential dividend cuts in holdings like Intel and Walgreens. The fund's broad diversification provides stability, but investors should weigh superior performance alternatives. Key risks include sector concentration and inflation pressures affecting dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
